Conventional drugs work, as a rule, by inhibiting the enzymatic activity of specific proteins, capping their active site. In this paper we present a model of non-conventional drug design based on the inhibiting effects small peptides obtained from segments of the protein itself have on the folding ability of the system. Such peptides attach to the newly expressed (unfolded) protein and inhibit its folding, inhibition which cannot be avoided but through mutations which in any case denaturate the enzyme. These peptides, or their mimetic molecules, can be used as effective alternative drugs to those already available, displaying the advantage of not suffering from the upraise of resistence.
Drugs perform their activity either by activating or by inhibiting some target component of the cell. In particular, many inhibitory drugs bind to an enzyme and deplete its function by preventing the binding of the substrate. This is done by either capping the active site of the enzyme (competitive inhibition) or, binding to some other part of the enzyme, by provoking structural changes which make the enzyme unfit to bind the substrate (allosteric inhibition).
The two main features that inhibitory drugs must display are efficiency and specificity.
In fact, it is not sufficient that the drug binds to the substrate and reduces efficiently its activity. It is also important that it does not interfere with other cellular processes, binding only to the protein it was designed for. These features are usually accomplished designing drugs which mimick the molecular properties of the natural substrate. In fact, the pair enzyme/substrate have undergone milions of years of evolution in order to display the required features. Consequently, the more similar the drug is to the substrate, the lower is the probability that it interferes with other cellular processes. Something that this kind of inhibitory drugs are not able to do is to avoid the development of resistance, a phenomenon which is typically related to viral protein targets. Under the selective pressure of the drug, the target is often able to either mutate the amino acids at the active site or at sites controlling its conformation in such a way that the activity of the enzyme is essentially retained, while the drug is no longer able to bind to it. An important example of drug-resistance is connected with AIDS. In this case, one of the main target proteins, HIV-protease, is able to mutate its active site so as to avoid the effects of drug action within a period of time of 6-8 months (cf. e.g. [1, 2] ). In the present paper we discuss the design of drugs which interfere with the folding mechanism of the target protein, destabilizing it and making it prone to proteolisis. We shall show that these drugs are efficient, specific and do not suffer from the upraise of resistance. The model of protein folding we employ is largely used in the literature. In spite of its simplicity, it reproduces well the thermodynamic and kinetic properties of real proteins [3, 4, 5] . The model describes a protein as a chain of beads sitting on a cubic lattice, each bead representing an amino acid and interacting with the neighbouring beads through a contact potential. There are twenty kinds of beads to account for the twenty kinds of natural amino acids. Consequently the contact potential is defined by a 20×20 matrix, extracted from statistical analysis of the contacts of real proteins [6] .
Using this model, it has been shown that single domain proteins fold according to a hierarchical mechanism [7, 8] . Starting from an elongated conformation, it is found that, highly conserved and strongly interacting amino-acids lying close along the designed chain form small local elementary structures (LES). Due to the small conformational space available and to their large attractive propensity, these LES are formed at a very early stage in the folding process and are very stable. The rate limiting step of this process corresponds to the assembly of the LES to build their native, non-local contacts(folding nucleus). This nucleation can be done in a relatively short time, because LES, moving as almost rigid entities, not only reduce the conformational space available to the protein but also display low probability of forming non-native interactions. Furthermore they interact with each other more strongly than single amino acids belonging to these structures do [8] . The nucleation event corresponds to the overcoming of the major free energy barrier found in the whole folding process [9] . After this is accomplished the remaining conformational space available to the protein is so small that the system reaches the native state almost immediately. In keeping with these results we suggest the use of short peptides with the same sequence as the LES (in the following, shortened as p-LES) to destabilize the protein. We test this suggestion on three sequences designed to fold to the three different structures displayed in To asses the ability p-LES display in destabilizing designed proteins, we have performed Monte Carlo simulations of a system composed of the protein and a number n p of p-LES in a cubic cell of linear size L with periodic boundary conditions [11] . Each simulation starts from a random conformation of the system and is carried on through 10
8 MC steps at fixed temperature T . During the simulation, we have collected the histogram of the order parameter q, defined as the relative number of native contacts, parameter which measures the extent to which the equilibrium state reached by the protein is similar to the native conformation.
In Fig. 2 (a) we display the equilibrium distribution of q, calulated at T = 0.24 and L = 7
for the system composed of sequence S36 and a number of p-LES 3'-6' as a function of n p (concentration) [12] . While the distribution of q values in the absence of p-LES (solid line)
shows a two-peaks shape, reflecting a all-none transition between the native (q > 0.7) and the unfolded (q < 0.6) state, the presence of p-LES reduces markedly the stability of the To further test the validity of these results, we have repeated the above calculations making use of peptides corresponding to segments of the protein sequence other than those corresponding to LES. In Fig. 2(d The thermodynamics which is at the basis of the disruptive mechanism of p-LES is quite simple. In fact there are three thermodynamically relevant states in the range of temperatures where the protein is stable: 1) the state in which the protein is folded and the n p p-LES do not interact with the protein (whose free energy is taken as reference and assigned a value ∆F 1 = 0), 2) the state in which a p-LES is bound to the (complementary)
LES of the protein preventing it from folding, its free energy being ∆F 2 = ∆F 0 + E LES + T S t − T log n p where the quantity ∆F 0 is the difference in free energy between the unfolded and the native state of the isolated protein, E LES is the interaction energy between the p-LES and the complementary LES and S t is the translational entropy of a p-LES, 3) the state in which the protein is unfolded and the p-LES do not interact with the protein, the associated free energy being ∆F 3 = ∆F 0 . The translational entropy can be estimated using the relation
where V = 343 is the volume of the cell (in lattice units) in which the simulations are performed, v prot = 166 is the average volume occupied by the protein, v ples = 20 is the average volume occupyied by a p-LES, while the prefactor 12 accounts for the orientation of the p-LES. It then follows that the equilibrium probability that the protein is folded, i.e.
in state 1), is given by indicates that E ′ ≪ E LES . In other words, the binding properties of the p-LES are highly specific. It could hardly have been different: since p-LES are identical to LES, a propensity of LES to bind some non-native part of the protein would imply the stabilization of a metastable state, something that evoultion tends to avoid.
In Fig. 3(d) we display the dependence of p 1 with temperature (solid dots) for the case of p-LES 3'-6'and n p = 2. The results of the simulations are well reproduced by the predictions obtained making use of Eq. (2). In these estimates the temperature dependence of ∆F 0 has been approximated with that of the Random Energy Model [7, 13] . The nonmonotonic behaviour of p 1 (T ) is a consequence of the competition between the stabilization of the native state and the decrease of the free energy of the unfolded states taking place as the temperature is lowered. At high temperatures, the state 3), which is independent on n p , becomes important, weakening the overall dependence of p 1 on n p . We have repeated the calculations described above, but this time making use of sequences obtained from S36 We have found that also the dynamical properties of p-LES make them suitable to be used as drugs. Starting from a random conformation of the protein and of the peptides, we have calculated the probability P (t) that the bond between residue 30 of the protein and 3' of any of the p-LES 3'-6' is formed as a function of time. This bond is chosen as representative of the interaction between the whole LES 27-30 and the p-LES 3'-6', the dynamics of the other bonds associated with the same LES being quite similar. The shape of the calculated probability function is well fitted by a single exponential
, where τ ′ is the characteristic time of bond formation. The dependence of τ ′ on the number n p of p-LES is displayed in Fig. 4 as a solid line, where it is compared to the average time needed for the p-LES to build the bond 30-3' with the protein after a random search in the volume of the cell, that is 12
The result obtained making use of this relation is also displayed in Fig. 4 (dashed curve).
The agreement with the result of the numerical simulations indicates that the random search is the actual mechanism which leads to the binding of the p-LES to its (complementary LES.
The fact that P (t) is well reproduced by a single exponential indicates furthermore that this is the only mechanism operative. In particular, this result excludes the possibility that the p-LES binds tightly to some other part of the protein. Such a scenario would produce a double-or more-fold-exponential shape of P (t).
To be noted that the binding time τ . This designed protein displays, in the folding process, three LES of length 2, 3 and 6, respectively. While the p-LES built of 6 residues inhibits folding as those described above, the other two p-LES do not. This is connected with the small size of these p-LES, which makes them quite unspecific. In fact, the probability that a p-LES binds to some part of the protein other than the target LES decreases exponentially with the number of residues involved.
We have shown that it is possible to inhibit the activity of a protein by disrupting its folding with the help of small peptides which mimick the LES of the protein. The very reason why LES make single domain proteins fold fast confers p-LES the required features to act as effective drugs, that is, efficiency and specificity. They are efficient because they bind as strongly as LES do. Since LES are responsible for the stability of the protein, their stabilization energy must be of the order of several times kT . These peptides are also as specific as LES are. In fact LES have evolved so as to prevent the upraise of metastable states and to avoid aggregation, aside of securing the protein to fold fast. The possibility of developing non-conventional drugs for actual situations is tantamount to being able to determine the LES for a given protein. This can be done either experimentally (e.g. making use of ϕ-value analysis [14] or ultrafast stopped flow experiments) or extending the algorithm discussed in ref. [10] making use of a realistic force field. The resulting peptides can be used either directly as drugs, or as templates to build mimetic molecules, which eventually do not display side effects connected with digestion or allergies.
A feature which makes, in principle, these drugs quite promising as compared to conventional ones is to be found in the fact that the target protein cannot evolve through mutations to escape the drug, as happens in particular in the case of viral proteins, because The associated designed sequences [7] are ( 
